Methods of treatment
The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
1. A method of treating a patient in need thereof with a CYP3A4 substrate drug, wherein the patient is treated with a strong CYP3A4 inhibitor,
comprising the steps of:
(a) stopping the strong CYP3A4 inhibitor treatment;
(b) delaying administering, for at least 9 days after stopping the strong CYP3A4 inhibitor treatment, a dose of the CYP3A4 substrate drug that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor; and then
(c) administering the dose of the CYP3A4 substrate drug;
wherein the CYP3A4 substrate drug is selected from the group consisting of tacrolimus, abemaciclib, encorafenib, larotrectinib, palbociclib, lorlatinib, axitinib, and irinotecan, and
wherein the strong CYP3A4 inhibitor is posaconazole.
2. The method of claim 1 , wherein the delaying in step (b) is 9 days.
3. The method of claim 1 , wherein the delaying in step (b) is 10 days.
4. The method of claim 1 , wherein the delaying in step (b) is 11 days.
5. The method of claim 1 , wherein the delaying in step (b) is 14 days.
6. The method claim 1 , wherein the delaying in step (b) is in the range of from 9-28 days.
7. The method of claim 1 , wherein the delaying in step (b) is in the range of from 9-42 days.
8. The method of claim 1 , wherein the delaying in step (b) is in the range of from 9-21 days.
9. The method of claim 1 , wherein the delaying in step (b) is in the range of from 14-28 days.
10. The method of claim 1 , wherein the patient is treated for a disease or condition selected from the group consisting of transplantation; hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer; hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; unresectable or metastatic melanoma with a BRAF V600E or V600K mutation; metastatic colorectal cancer (CRC) with a BRAF V600E mutation; adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment; hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men or fulvestrant in patients with disease progression following endocrine therapy; metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive; advanced renal cell carcinoma (RCC); and metastatic adenocarcinoma of the pancreas.
11. The method of claim 1 , wherein the CYP3A4 substrate drug is tacrolimus.
12. The method of claim 1 , wherein the CYP3A4 substrate drug is abemaciclib.
13. The method of claim 1 , wherein the CYP3A4 substrate drug is encorafenib.
14. The method of claim 1 , wherein the CYP3A4 substrate drug is larotrectinib.
15. The method of claim 1 , wherein the CYP3A4 substrate drug is palbociclib.
16. The method of claim 1 , wherein the CYP3A4 substrate drug is lorlatinib.
17. The method of claim 1 , wherein the CYP3A4 substrate drug is axitinib.
18. The method of claim 1 , wherein the CYP3A4 substrate drug is irinotecan.